VivoSim Labs | 10-Q: FY2026 Q1 Revenue: USD 37 K

Revenue: As of FY2026 Q1, the actual value is USD 37 K.

EPS: As of FY2026 Q1, the actual value is USD -1.14.

Segment Revenue

• Royalty Revenue: $37,000 for the three months ended June 30, 2025, compared to $25,000 for the same period in 2024, representing a 48% increase.
• Product Revenue: $0 for the three months ended June 30, 2025, compared to $14,000 for the same period in 2024, indicating a 100% decrease due to the end of operations of the Mosaic division.

Operational Metrics

• Net Loss: $2.843 million for the three months ended June 30, 2025, compared to $3.344 million for the same period in 2024, showing an improvement.
• Research and Development Expenses: $1.001 million for the three months ended June 30, 2025, a decrease of 29% from $1.402 million in the same period in 2024.
• Selling, General and Administrative Expenses: $1.951 million for the three months ended June 30, 2025, a slight decrease from $2.021 million in the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $3.940 million for the three months ended June 30, 2025, compared to - $2.983 million for the same period in 2024, indicating increased cash usage.
• Net Cash Provided by Financing Activities: $1.683 million for the three months ended June 30, 2025, compared to $6.249 million for the same period in 2024.

Unique Metrics

• Stock-Based Compensation: $78,000 for the three months ended June 30, 2025, compared to $156,000 for the same period in 2024, reflecting a 50% decrease.

Future Outlook and Strategy

• Core Business Focus: VivoSim Labs, Inc. plans to continue advancing its Preclinical IBD Program with the goal of having a product candidate ready for an IND Application with the FDA by December 2026. The company is also focusing on offering liver toxicology predictive screening and research services to reduce the risk and cost of bringing therapeutics to market.
• Non-Core Business: The company sold its FXR program for $10.0 million, with potential future milestone payments of up to $50.0 million, indicating a strategic shift away from this program.